Der Diabetologe

, Volume 7, Issue 8, pp 568–575 | Cite as

Tertiärprävention des Typ-1-Diabetes

Leitthema
  • 127 Downloads

Zusammenfassung

Ansätze zur Tertiärprävention des Typ-1-Diabetes umfassen Interventionen bei oder kurz nach der Manifestation der Hyperglykämie bei bereits fortgeschrittener β-Zell-Destruktion. Ziel der Interventionen ist eine Reversion des Diabetes oder zumindest eine verlangsamte Progression durch den möglichst langfristigen Erhalt der verbleibenden β-Zell-Funktion. Hierbei werden antigengerichtete Ansätze [Behandlung mit Inselantigenen wie Glutamatdecarboxylase (GAD) oder Hitzeschockprotein-60-Peptid (DiaPep277)] von antientzündlichen Behandlungen (Interleukin-1-Rezeptorantagonist, IL-1-RA, Atorvastatin) oder immunzellgerichteten Behandlungen (Anti-CD3, Anti-CD20, Abatacept) unterschieden. Obwohl die bisherigen Studienergebnisse darauf hinweisen, dass die Aufrechterhaltung der noch vorhandenen β-Zell-Funktion prinzipiell möglich ist, hat sich bisher noch keine gesicherte Therapieform etabliert. Nachdem niedrig-dosierte Anti-CD3-Gabe und auch die Vakzinierung mit GAD nicht die erhofften Erfolge zeigten, werden die Ergebnisse aktuell laufender Phase-II/III-Studien zur Tertiärprävention durch andere Ansätze und weitere Erkenntnisse aus Studien zur Stammzelltransplantation mit Spannung erwartet.

Schlüsselwörter

β-Zellen, pankreatisch Glutamatdecarboxylase Antigene, CD3 Stammzellen C-Peptid 

Tertiary prevention of type 1 diabetes

Abstract

Tertiary prevention in patients with type 1 diabetes comprises interventions at or shortly after primary manifestation of hyperglycemia when the majority of ß-cells have already been destroyed. The interventions aim to reverse diabetes or at least to ameliorate further progression of ß-cell loss and long-term stabilization of endogenous insulin secretion capability. Antigen-directed therapy and treatment with islet antigens, such as glutamic acid decarboxylase (GAD) or heat shock protein 60 peptide (DiaPep277), as well as anti-inflammatory treatment with atorvastatin, interleukin 1 receptor antagonist (IL1RA) or immune cell directed treatment (anti-CD3, anti-CD20, abatacept) are currently under investigation. Although recent studies suggest that maintaining ß-cell function is possible, there are currently no approved forms of treatment that can be recommended as standard therapy. After low dose anti-CD3 and also treatment with GAD did not show the success expected in recent phase III studies, results from ongoing phase II/III studies for tertiary prevention and further results on stem cell therapy are eagerly awaited.

Keywords

Beta cells, pancreatic Glutamate decarboxylase Antigens, CD3 Stem cells C-peptide 

Notes

Danksagung

Wir danken Hubert Kolb für die Durchsicht des Manuskripts.

Interessenkonflikt

Die korrespondierende Autorin weist auf folgende Beziehungen hin: N.C. Schloot ist Mitarbeiterin der Fa. Lilly Deutschland und vorübergehend vom Deutschen Diabetes-Zentrum beurlaubt. Sie hat Beraterhonorare der Firmen Andromeda Rehovot, Israel, Sensile Medical, Boehringer-Ingelheim und Glaxo-Smith Cline erhalten. Sie war als Referentin für Novo Nordisk, Sanofi- Aventis und im Rahmen des Praxis Update tätig. N.C. Schloot und S. Link waren/sind an der Durchführung von klinischen Studien der Firmen Andromeda, Tolerx, Boehringer-Ingelheim, Bayer und Roche am Deutschen Diabetes-Zentrum beteiligt.

Literatur

  1. 1.
    Aly H, Gottlieb P (2009) The honeymoon phase: intersection of metabolism and immunology. Curr Opin Endocrinol Diabetes Obes 16:286–292PubMedCrossRefGoogle Scholar
  2. 2.
    Cernea S, Raz I, Herold KC et al (2009) Challenges in developing endpoints for type 1 diabetes intervention studies. Diabetes Metab Res Rev 25:694–704PubMedCrossRefGoogle Scholar
  3. 3.
    Eisenbarth GS (1985) Type I diabetes mellitus. A chronic autoimmune disease. N Engl J Med 314:1360–1368Google Scholar
  4. 4.
    Greenbaum CJ, Mandrup-Poulsen T, McGee PF et al; European C-Peptide Trial Study Group (2008) Mixed-meal tolerance test versus glucagon stimulation test for the assessment of beta-cell function in therapeutic trials in type 1 diabetes. Diabetes Care 31:1966–1971PubMedCrossRefGoogle Scholar
  5. 5.
    Herold KC, Gitelman S, Greenbaum C et al; Immune Tolerance Network ITN007AI Study Group (2009) Treatment of patients with new onset type 1 diabetes with a single course of anti-CD3 mAb teplizumab preserves insulin production for up to 5 years. Clin Immunol 132:166–173PubMedCrossRefGoogle Scholar
  6. 6.
    Huurman VA, Decochez K, Mathieu C et al (2007) Therapy with the hsp60 peptide DiaPep277 in C-peptide positive type 1 diabetes patients. Diabetes Metab Res Rev 23:269–275PubMedCrossRefGoogle Scholar
  7. 7.
    Keymeulen B, Vandemeulebroucke E, Ziegler AG et al (2005) Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med 352:2598–2608PubMedCrossRefGoogle Scholar
  8. 8.
    Keymeulen B, Walter M, Mathieu C et al (2010) Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass. Diabetologia 53:614–623PubMedCrossRefGoogle Scholar
  9. 9.
    Kilpatrick ES, Rigby AS, Atkin SL (2009) Effect of glucose variability on the long-term risk of microvascular complications in type 1 diabetes. Diabetes Care 32:1901–1903PubMedCrossRefGoogle Scholar
  10. 10.
    Lazar L, Ofan R, Weintrob N et al (2007) Heat-shock protein peptide DiaPep277 treatment in children with newly diagnosed type 1 diabetes: a randomised, double-blind phase II study. Diabetes Metab Res Rev 23:286–291PubMedCrossRefGoogle Scholar
  11. 11.
    Ludvigsson J, Faresjö M, Hjorth M et al (2008) GAD treatment and insulin secretion in recent-onset type 1 diabetes. N Engl J Med 359:1909–1920PubMedCrossRefGoogle Scholar
  12. 12.
    Ludvigsson J, Hjorth M, Chéramy M et al (2011) Extended evaluation of the safety and efficacy of GAD treatment of children and adolescents with recent-onset type 1 diabetes: a randomised controlled trial. Diabetologia 54:634–640PubMedCrossRefGoogle Scholar
  13. 13.
    Mandrup-Poulsen T, Pickersgill L, Donath MY (2010) Blockade of interleukin 1 in type 1 diabetes mellitus. Nat Rev Endocrinol 6:158–166PubMedCrossRefGoogle Scholar
  14. 14.
    Martin S, Herder C, Schloot NC et al (2011) Residual beta cell function in newly diagnosed type 1 diabetes after treatment with atorvastatin: the Randomized DIATOR Trial. PLoS One 6:e17554PubMedCrossRefGoogle Scholar
  15. 15.
    Mastrandrea L, Yu J, Behrens T et al (2009) Etanercept treatment in children with new-onset type 1 diabetes: pilot randomized, placebo-controlled, double-blind study. Diabetes Care 32:1244–1249PubMedCrossRefGoogle Scholar
  16. 16.
    Orban T, Bundy B, Becker DJ et al (2011) Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial. Lancet 378(9789):412–419PubMedCrossRefGoogle Scholar
  17. 17.
    Palmer JP, Fleming GA, Greenbaum CJ et al (2004) C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve beta-cell function: report of an ADA workshop, 21–22 October 2001. Diabetes 53:250–264PubMedCrossRefGoogle Scholar
  18. 18.
    Pescovitz MD, Greenbaum CJ, Krause-Steinrauf H et al (2009) Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. N Engl J Med 361:2143–2152PubMedCrossRefGoogle Scholar
  19. 19.
    Pfleger C, Mortensen HB, Hansen L et al (2008) Association of IL-1ra and adiponectin with C-peptide and remission in patients with type 1 diabetes. Diabetes 57:929–937PubMedCrossRefGoogle Scholar
  20. 20.
    Raz I, Elias D, Avron A et al (2001) Beta-cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277): a randomised, double-blind, phase II trial. Lancet 358(9295):1749–1753PubMedCrossRefGoogle Scholar
  21. 21.
    Roep BO (2003) The role of T-cells in the pathogenesis of type 1 diabetes: from cause to cure. Diabetologia 46:305–321PubMedGoogle Scholar
  22. 22.
    Rossetti L (2004) Glucose toxicity: effect of chronic hyperglycemia on insulin action. Diabetes mellitus: a fundamental and clinical text, 3. Aufl. Lippincott Wiliams & Wilkins, PhiladelphiaGoogle Scholar
  23. 23.
    Rother KI, Brown RJ, Morales MM et al (2009) Effect of ingested interferon-alpha on beta-cell function in children with new-onset type 1 diabetes. Diabetes Care 32:1250–1255PubMedCrossRefGoogle Scholar
  24. 24.
    Schloot NC, Meierhoff G, Lengyel C et al (2007) Effect of heat shock protein peptide DiaPep277 on beta-cell function in paediatric and adult patients with recent-onset diabetes mellitus type 1: two prospective, randomized, double-blind phase II trials. Diabetes Metab Res Rev 23:276–285PubMedCrossRefGoogle Scholar
  25. 25.
    Schloot NC, Roden M, Bornstein SR, Brendel MD (2011) Recent advances in the treatment of type 1 diabetes mellitus. Dtsch Med Wochenschr 136:172–175PubMedCrossRefGoogle Scholar
  26. 26.
    Sherry N, Hagopian W, Ludvigsson J et al (2011) Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial. Lancet 378(9790):487–497PubMedCrossRefGoogle Scholar
  27. 27.
    Steffes MW, Sibley S, Jackson M, Thomas W (2003) Beta-cell function and the development of diabetes-related complications in the diabetes control and complications trial. Diabetes Care 26:832–836PubMedCrossRefGoogle Scholar
  28. 28.
    The DCCT Research Group (1998) Effect of intensive therapy on residual β-cell function in patients with type 1 diabetes in the Diabetes Control and Complications Trial. A randomized, controlled trial. Ann Intern Med 128:517–523Google Scholar
  29. 29.
    Wherrett DK, Bundy B, Becker DJ et al (2011) Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial. Lancet 378(9788):319–327PubMedCrossRefGoogle Scholar
  30. 30.
    Yki-Järvinen H, Koivisto VA (1986) Natural course of insulin resistance in type I diabetes. N Engl J Med 315:224–230PubMedCrossRefGoogle Scholar
  31. 31.
    Zahiragic L, Schloot NC (2011) Prävention des Typ 1 Diabetes. Erste Erfolge gegen die Autoimmunität Info. Diabetologie 5:26–30Google Scholar
  32. 32.
    Couri CE, Oliveira MC, Stracieri AB et al (2009) Hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. JAMA 301:1573–1579PubMedCrossRefGoogle Scholar
  33. 33.
    Matthews JB, Staeva TP, Bernstein PL et al (2010) Developing combination immunotherapies for type 1 diabetes: recommendations from the ITN-JDRF Type 1 Diabetes Combination Therapy Assessment Group. Clin Exp Immunol 160:176–184PubMedCrossRefGoogle Scholar
  34. 34.
    Shoda LK, Young DL, Ramanujan S et al (2005) A comprehensive review of interventions in the NOD mouse and implications for translation. Immunity 23:115–126PubMedCrossRefGoogle Scholar
  35. 35.
    Haller MJ, Wasserfall CH, McGrail KM et al (2009) Autologous umbilical cord blood transfusion in very young children with type 1 diabetes. Diabetes Care 32:2041–2046PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  1. 1.Institut für Klinische Diabetologie, Deutsches Diabetes-Zentrum, Leibniz-Zentrum für DiabetesforschungHeinrich-Heine-UniversitätDüsseldorfDeutschland
  2. 2.Klinik für StoffwechselkrankheitenUniversitätsklinikum DüsseldorfDüsseldorfDeutschland
  3. 3.Lilly DeutschlandBad HomburgDeutschland

Personalised recommendations